Table 2. . Paclitaxel Tc >0.05 and Cmax by phenotype predicted metabolizer status.
| Gene | Poor | Intermediate | Normal | Ultra-rapid | Univariate association |
|---|---|---|---|---|---|
| Primary analysis | Mean Tc >0.05 (h ) (SD) stratified by phenotype | β (95% CI), p-value | |||
| CYP2C8 | 9.65 (2.06) n = 17 |
11.03 (2.74) n = 40 |
† | β = 1.13 (1.01–1.28) p = 0.046* |
|
| Secondary analysis | Mean Tc >0.05 (h ) (SD) stratified by phenotype or genotype | β (95% CI), p-value | |||
| CYP2C8 *1/*3 and *3/*3 | 8.92 (1.00) n = 12 |
11.03 (2.74) n = 40 |
† | β = 0.82 (0.72–0.94) p = 0.006* |
|
| CYP2C8 *1/*4 and *4/*4 | 10.25 (1.71) n = 4 |
11.03 (2.74) n = 40 |
† | β = 0.94 (0.76–1.17) p = 0.58 |
|
| CYP3A4 | 12.00 (2.83) n = 8 |
10.52 (2.68) n = 50 |
† | β = 1.14 (0.97–1.35) p = 0.12 |
|
| CYP3A5 | 10.64 (2.72) n = 48 |
10.83 (2.04) n = 6 |
– n = 0 |
† | β = 1.03 (0.85–1.24) p = 0.76 |
| ABCB1 | 10.91 (3.48) n = 22 |
10.55 (2.33) n = 20 |
10.29 (1.33) n = 14 |
† | β = 0.99 (0.92–1.06) p = 0.73 |
| ABCC2 | 10.67 (1.53) n = 3 |
10.83 (3.05) n = 30 |
10.67 (2.28) n = 18 |
9.33 (1.37) n = 6 |
β = 0.96 (0.89–1.04) p = 0.33 |
| ABCG2 | – n = 0 |
9.67 (2.50) n = 9 |
10.92 (2.74) n = 49 |
† | β = 0.88 (0.75–1.04) p = 0.14 |
| SLCO1B1 | 12.12 (3.60) n = 17 |
10.15 (2.06) n = 41 |
† | β = 1.17 (1.03–1.33) p = 0.014* |
|
| SLCO1B3 | 10.88 (2.92) n = 40 |
10.79 (2.39) n = 14 |
8.67 (1.15) n = 3 |
† | β = 0.95 (0.86–1.05) p = 0.32 |
| Secondary analysis | Mean Cmax (ng/ml ) (SD) stratified by phenotype | β (95% CI), p-value | |||
| CYP2C8 | 2187.33 (656.90) n = 15 |
2455.75 (632.08) n = 40 |
† | β = 268.42 (-119.46–656.30) p = 0.17 |
|
| CYP2C8 *1/*3 and *3/*3 | 1985.00 (594.76) n = 12 |
2455.75 (632.08) n = 40 |
† | β = -320.75 (-767.56–126.06) p = 0.16 |
|
| CYP2C8 *1/*4 and *4/*4 | 2550.00 (693.83) n = 4 |
2455.75 (632.08) n = 40 |
† | β = 94.25 (-568.47–756.97) p = 0.78 |
|
| CYP3A4 | 2250.00 (458.11) n = 7 |
2410.20 (664.14) n = 49 |
† | β = -160.20 (-682.31–361.91) p = 0.54 |
|
| CYP3A5 | 2413.26 (679.75) n = 46 |
2226.67 (500.63) n = 6 |
– n = 0 |
† | β = -186.59 (-765.50–392.31) p = 0.52 |
| ABCB1 | 2219.05 (636.73) n = 21 |
2405.79 (782.05) n = 19 |
2585.00 (403.94) n = 14 |
† | β = 183.25 (-36.39–402.88) p = 0.10 |
| ABCC2 | 2316.67 (560.03) n = 3 |
2304.67 (672.21) n = 30 |
2595.00 (683.64) n = 16 |
2238.33 (353.52) n = 6 |
β = 58.99 (-172.31–290.30) p = 0.61 |
| ABCG2 | – n = 0 |
2233.75 (517.19) n = 8 |
2416.25 (660.23) n = 48 |
† | β = -182.50 (-675.17–310.17) p = 0.46 |
| SLCO1B1 | 2407.06 (725.44) n = 17 |
2382.82 (610.46) n = 39 |
† | β = 24.24 (-352.55–401.03) p = 0.90 |
|
| SLCO1B3 | 2390.00 (699.39) n = 38 |
2432.86 (565.22) n = 14 |
2143.33 (230.29) n = 3 |
† | β = -44.27 (-346.45–257.91) p = 0.77 |
*Statisticaly significant.
†Denotes phenotype groups that did not exist for that gene (See Supplementary Table 2).
SD: Standard deviation.